This article is currently under investigation. We strongly recommend that this article is not cited until the investigation is completed.
Research Paper Volume 11, Issue 18 pp 7678—7693
Long noncoding RNA TTN-AS1 enhances the malignant characteristics of osteosarcoma by acting as a competing endogenous RNA on microRNA-376a thereby upregulating dickkopf-1
Figure 3. TTN-AS1 functions as a ceRNA for miR-376a in OS cells. (A) The distribution of TTN-AS1 within OS cells was determined by the nuclear/cytoplasmic fractionation assay. (B) The wild-type miR-376a-binding sequences in TTN-AS1, as predicted by starBase 3.0. The mutations in the TTN-AS1 sequence that disrupt the interaction between TTN-AS1 and miR-376a are shown too. (C) HOS and MG-63 cells that were transfected with either agomir-376a or agomir-NC were harvested and analyzed for miR-376a expression by RT-qPCR. *P < 0.05 vs. the agomir-NC group. (D) Luciferase reporter assays were performed on HOS and MG-63 cells that were transfected with either agomir-376a or agomir-NC and either TTN-AS1-wt or TTN-AS1-mut. *P < 0.05 vs. group agomir-NC. (E) The RIP assay was conducted to assess the direct interaction between TTN-AS1 and miR-376a. *P < 0.05 vs. the IgG group. (F) The expression profile of miR-376a in the 47 pairs of OS tissues and adjacent-normal-bone tissue samples was analyzed by RT-qPCR. *P < 0.05 vs. the normal bone tissues. (G) An inverse correlation between TTN-AS1 and miR-376a expression levels was validated in the OS tissue samples by Spearman’s correlation analysis. r = -0.6751, P < 0.0001. (H) Expression of miR-376a in HOS and MG-63 cells transfected with either si-TTN-AS1 or si-NC was determined by RT-qPCR. *P < 0.05 vs. the si-NC group.